Novel antiplatelet agent ticagrelor in the management of acute coronary syndrome.
Abstract
Current clinical guidelines recommend dual antiplatelet agents namely aspirin and
clopidogrel for the treatment of patients suffering from acute coronary syndrome (ACS).
But the efficacy of clopidogrel is variable as it is a pro-drug, which has to be metabolized
to become an active drug thus exhibiting variable platelet inhibition, increases risk
of bleeding, stent thrombosis, and ischemia. To overcome this limitation, prasugrel
was developed with increased antiplatelet activity thereby reducing the risk of myocardial
ischemia and stent thrombosis. This action of prasugrel was associated with an increased
risk of major bleeding. Finally, a novel reversible and direct-acting oral adenosine
diphosphate (ADP) receptor antagonist, ticagrelor was developed that showed consistent
and increased P2Y12 inhibition with similar incidence of bleeding but greater reduction
in cardiac events compared to clopidogrel. The focus of this article is to review
ticagrelor as a new class of P2Y12 inhibitor.
Type
Journal articlePermalink
https://hdl.handle.net/10161/18599Published Version (Please cite this version)
10.1111/j.1540-8183.2010.00613.xPublication Info
Ramaraj, Radhakrishnan; Movahed, Mohammad Reza; & Hashemzadeh, Mehrnoosh (2011). Novel antiplatelet agent ticagrelor in the management of acute coronary syndrome.
Journal of interventional cardiology, 24(3). pp. 199-207. 10.1111/j.1540-8183.2010.00613.x. Retrieved from https://hdl.handle.net/10161/18599.This is constructed from limited available data and may be imprecise. To cite this
article, please review & use the official citation provided by the journal.
Collections
More Info
Show full item recordScholars@Duke
Radhakrishnan Ramaraj
Clinical Associate in the Department of Medicine
This author no longer has a Scholars@Duke profile, so the information shown here reflects
their Duke status at the time this item was deposited.

Articles written by Duke faculty are made available through the campus open access policy. For more information see: Duke Open Access Policy
Rights for Collection: Scholarly Articles
Works are deposited here by their authors, and represent their research and opinions, not that of Duke University. Some materials and descriptions may include offensive content. More info